Details:
The financing will develop the company's unique process that enables discovery and manufacture of next generation TCR-T-based cell therapies for cancer on an industrial scale. The financing also allows Anocca to progress the company's first products into clinical trials.
Lead Product(s): TCR-T-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AMF
Deal Size: $36.5 million Upfront Cash: Undisclosed
Deal Type: Financing May 31, 2023
Details:
Lonza will integrate Simris’ antibody-drug conjugate payload technology into the Lonza Bioconjugation Toolbox and will gain the exclusive right to offer the technology to new and existing customers seeking novel payloads to develop into ADC medicines.
Lead Product(s): Antibody-Drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Lonza Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 10, 2023
Details:
As part of the termination, both Dong-A ST and Beactica Therapeutics will gain exclusive global rights for further development and commercialization for different compounds series developed during the collaboration.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Dong-A ST Co., Ltd.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination September 06, 2022
Details:
Under the terms of the agreement, Oscotec is entitled to gain exclusive global rights for further development and commercialization of Beactica's programme.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Oscotec
Deal Size: $17.8 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 02, 2021